Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals

Rita P. Cervera; Miodrag Stojkovic

doi:10.1002/9783527669417.ch2

Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter aims to introduce current and future uses of human embryonic stem cells (hESC) derived from in vitro fertilized embryos. These and stem cells derived from parthenogenetic and nuclear transfer embryos could be used for cell therapy, as in vitro cell models for drug discovery/screening and for studying early human development and pathogenesis of human diseases. However, development of therapeutic and screening applications and products from hESC is hampered by several barriers. Therefore, gaps in our current understanding of stem cell basic science need to be filled before either application can move forward with confidence for biopharmaceutical development.

Original language	English (US)
Title of host publication	Modern Biopharmaceuticals
Subtitle of host publication	Recent Success Stories
Publisher	Wiley-VCH
Pages	39-55
Number of pages	17
ISBN (Print)	9783527322831
DOIs	https://doi.org/10.1002/9783527669417.ch2
State	Published - Apr 23 2013
Externally published	Yes

Keywords

Differentiation
Human embryonic stem cells
Induced pluripotency
Nuclear transfer
Signaling pathway
Somatic cells

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1002/9783527669417.ch2

Cite this

@inbook{01467734bdb34493bd443afdf0999cb5,

title = "Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals",

abstract = "This chapter aims to introduce current and future uses of human embryonic stem cells (hESC) derived from in vitro fertilized embryos. These and stem cells derived from parthenogenetic and nuclear transfer embryos could be used for cell therapy, as in vitro cell models for drug discovery/screening and for studying early human development and pathogenesis of human diseases. However, development of therapeutic and screening applications and products from hESC is hampered by several barriers. Therefore, gaps in our current understanding of stem cell basic science need to be filled before either application can move forward with confidence for biopharmaceutical development.",

keywords = "Differentiation, Human embryonic stem cells, Induced pluripotency, Nuclear transfer, Signaling pathway, Somatic cells",

author = "Cervera, {Rita P.} and Miodrag Stojkovic",

year = "2013",

month = apr,

day = "23",

doi = "10.1002/9783527669417.ch2",

language = "English (US)",

isbn = "9783527322831",

pages = "39--55",

booktitle = "Modern Biopharmaceuticals",

publisher = "Wiley-VCH",

}

TY - CHAP

T1 - Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals

AU - Cervera, Rita P.

AU - Stojkovic, Miodrag

PY - 2013/4/23

Y1 - 2013/4/23

N2 - This chapter aims to introduce current and future uses of human embryonic stem cells (hESC) derived from in vitro fertilized embryos. These and stem cells derived from parthenogenetic and nuclear transfer embryos could be used for cell therapy, as in vitro cell models for drug discovery/screening and for studying early human development and pathogenesis of human diseases. However, development of therapeutic and screening applications and products from hESC is hampered by several barriers. Therefore, gaps in our current understanding of stem cell basic science need to be filled before either application can move forward with confidence for biopharmaceutical development.

AB - This chapter aims to introduce current and future uses of human embryonic stem cells (hESC) derived from in vitro fertilized embryos. These and stem cells derived from parthenogenetic and nuclear transfer embryos could be used for cell therapy, as in vitro cell models for drug discovery/screening and for studying early human development and pathogenesis of human diseases. However, development of therapeutic and screening applications and products from hESC is hampered by several barriers. Therefore, gaps in our current understanding of stem cell basic science need to be filled before either application can move forward with confidence for biopharmaceutical development.

KW - Differentiation

KW - Human embryonic stem cells

KW - Induced pluripotency

KW - Nuclear transfer

KW - Signaling pathway

KW - Somatic cells

UR - http://www.scopus.com/inward/record.url?scp=84885550258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885550258&partnerID=8YFLogxK

U2 - 10.1002/9783527669417.ch2

DO - 10.1002/9783527669417.ch2

M3 - Chapter

AN - SCOPUS:84885550258

SN - 9783527322831

SP - 39

EP - 55

BT - Modern Biopharmaceuticals

PB - Wiley-VCH

ER -

Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this